Key Highlights

  • Sono-Tek (NASDAQ:SOTK) rose 7.79% to USD 5.67 in early trading on Monday, October 26, 2026; the company has not issued a release dated that day explaining the move.
  • First-half fiscal 2027 revenue was USD 10.9 million, up 6%, with medical market revenue of USD 7.1 million, up 289%, as presented on the company call of Wednesday, October 14, 2026.
  • Gross margin for the half rose to 55% from 51%, and the combined clean energy and medical diagnostic backlog stood at USD 10.8 million, mostly shipping in fiscal 2028.
  • The company holds USD 17.7 million of cash with no debt, and it kept guidance for flat to modest revenue growth in fiscal 2027.

Sono-Tek Advances on Backlog and Medical Momentum

Sono-Tek Corporation (NASDAQ:SOTK), which makes ultrasonic coating systems used in medical devices, electronics and clean energy, rose 7.79% to USD 5.67 in early trading on Monday, October 26, 2026, with prices described as intraday. The company has not issued a release dated that day explaining the move. The most recent substantive update was its fiscal second quarter and first half 2027 results, discussed on a call on Wednesday, October 14, 2026. First-half revenue reached USD 10.9 million, up 6%, while medical market revenue rose 289% to USD 7.1 million as customers moved from process development to commercial manufacturing.

How Medical Production Orders Lift Margins and Visibility

Sono-Tek (NASDAQ:SOTK) earns more on production-scale equipment than on development units, because commercial lines carry higher unit prices and margins. Gross margin for the half rose to 55% from 51%, consistent with that shift. Two large orders anchor the backlog of USD 10.8 million: a record order of more than USD 3.6 million for a medical diagnostic production line, announced in August 2026, and an alternative energy order for 10 production-scale systems valued at USD 7.2 million across three factory locations. Most units ship in fiscal 2028, which gives revenue visibility beyond the current year, although a backlog is a commitment and not a recognised sale.

Risks and What to Watch

The main risk for Sono-Tek (NASDAQ:SOTK) is timing. Management kept guidance for flat to modest revenue growth in fiscal 2027, and because most of the backlog ships in fiscal 2028, near-term sales may not reflect it. Customer concentration is a second factor, as a small number of large orders drive both medical and energy revenue. The balance sheet is a strength, with USD 17.7 million of cash and no debt, which reduces financing risk for a small company. The company has not announced its next results date. In the meantime, the Federal Reserve decision on Wednesday, October 28, 2026 may influence capital spending sentiment among its equipment customers.

Where Things Stand

The answer is that the advance at Sono-Tek (NASDAQ:SOTK) fits a backlog and margin story rather than a new announcement. The company has not issued a release explaining Monday's move, and the shares at USD 5.67 reflect first-half revenue of USD 10.9 million, a 55% gross margin, a USD 10.8 million backlog and USD 17.7 million of cash. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026 and any further production orders from medical or clean energy customers. Small caps trade in thin volume and can reverse quickly, and this is not investment advice.